Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.86
Revised: January 22, 2014
Accepted: April 16, 2014
Published online: May 10, 2014
Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage IB2-IIB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries. Thus, radical concurrent chemoradiation is the standard of care in United Sated and Canada, and neoadjuvant chemotherapy followed by radical surgery is the first line of treatment in some institutions of Europe, Asia and Latin America. Until today, there is no evidence of which strategy is better over the other. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment for women affected by uterine cervical cancer stage IB2-IIB.
Core tip: There is no currenty demonstrated the best option of treatment for women with locally advanced cervical cancer Federation of Gynecology and Obstetrics stage IB2-IIB. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment.